Key points from article :
“Longevity pharmacology field to revolutionize the healthcare of a growing aging population,” - João Pedro de Magalhães, Integrative Genomics of Ageing Group at the University of Liverpool.
“Computational approaches can identify longevity drugs with higher probability of working in humans with minimal side effects.”
“Having a greater diversity of animal models and mouse strains employed in research, will be beneficial.”
Aging can be pharmacologically retarded in animals; “...we need to do trials in humans.”
The future of longevity pharmacology is linked to biomarkers and personalised regimens.
“…ultimately what I would like is a drug that retards aging in everybody.”
At Centaura, “We’re developing technologies for gene therapy, specifically artificial chromosomes.”
“If I had to choose a pharmacological approach to aging then that would be rapamycin, such as rapalogs safer than rapamycin but have similar benefits.”
Feature article published in the journal Drug Discovery Today.
